Lewes, DE -- (SBWire) -- 07/22/2013 --LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Out Today’s Focus is on: Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), Warner Chilcott Plc (NASDAQ:WCRX), Avanir Pharmaceuticals Inc (NASDAQ:AVNR), Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)

Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) increased 16.50% and closed at $1.20 on a traded volume of 5.17 million shares, in comparison to 1.01 million shares of average trading volume. So far this year, the stock is down over 39.53%.

The company has a total market capitalization of $49.70 million and its total outstanding shares are 41.42million.

Will CPRX Continue To Move Higher? Find Out Here

Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company. The Company is focused on the development and commercialization of prescription drugs targeting addiction diseases and disorders of the central nervous system with a focus on the treatment of addiction and epilepsy.

Warner Chilcott Plc (NASDAQ:WCRX) soared 0.66% and closed at $19.87 on a traded volume of 2.27 million shares, whereas its average trading volume is 3.73 million shares. In the last three months, the stock is down 43.16%. The Intra-day range for the stock is $19.62 and $19.99.

Will WCRX Continue To Move Higher? Find Out Here

Warner Chilcott Public Limited Company is a specialty pharmaceutical company. It is focused on the women’s healthcare, gastroenterology, dermatology and urology segments of the branded pharmaceuticals market, primarily in North America. It is an integrated company with internal resources focused on the development, manufacture and promotion of its products.

Avanir Pharmaceuticals Inc (NASDAQ:AVNR) jumped up 4.00% and closed at $4.81. So far in three months, the stock is up 60.33%. The 52-week range for the stock is $2.07 and $4.85 and during the previous trading session the stock touched its highest price at $4.85 Its introductory price for the day was $4.60, with the overall traded volume of 2.07 million shares.

Will AVNR Continue To Move Higher? Find Out Here

AVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system.

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) after opening its shares at the price of $15.08, jumped up 3.12% to close at $15.55 for the day. The stock moved on a traded volume of 1.77 million shares, in comparison to 380,648shares of average trading volume.

The 52-week range for the stock is $10.05 and $15.81 and during the previous trading session the stock touched its highest price at $15.81. Its introductory price for the day was $15.08.

Will MNTA Continue To Move Higher? Find Out Here

Momenta Pharmaceuticals, Inc. (Momenta) is a biotechnology company specializing in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs).

About LeadingStockAlerts
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.

Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.

Disclaimer
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Read Full Disclaimer at: http://leadingstockalerts.com/disclaimer/